Primary hyperoxaluria type 1 (PH1) is a metabolic stone disease that, if left undiagnosed, can have devastating consequences, including progressive kidney decline and end-stage kidney disease (ESKD).

PH1 is a rare condition with potentially devastating consequences, especially when onset occurs early in life. Are you up to date with recent developments? Take this quiz to find out. At the end ...

YolTech Therapeutics reports positive clinical data for YOLT-203, an in vivo gene editing therapy for primary hyperoxaluria type 1: Shanghai, China Wednesday, February 26, 2025, 1 ...

to treat primary hyperoxaluria type 1 (PH1). The orphan drug and rare paediatric disease designations will offer the company incentives such as tax credits, exemption from certain regulatory ...

Primary Hyperoxaluria (PH) is a rare autosomal recessive ... leading to excessive oxalate production and systemic oxalate deposition. PH1, the most common subtype, is triggered by AGXT gene ...

Primary Hyperoxaluria (PH) is a rare autosomal recessive genetic disorder caused by enzyme deficiencies in hepatic oxalate metabolism, leading to excessive oxalate production and systemic oxalate ...

With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company dedicated to transforming ...

Tue, Feb 25, 2025, 3:15 AM 4 min read ...